ES2054137T3 - Conjugados para la localizacion y/o la terapia de los tumores. - Google Patents

Conjugados para la localizacion y/o la terapia de los tumores.

Info

Publication number
ES2054137T3
ES2054137T3 ES90107187T ES90107187T ES2054137T3 ES 2054137 T3 ES2054137 T3 ES 2054137T3 ES 90107187 T ES90107187 T ES 90107187T ES 90107187 T ES90107187 T ES 90107187T ES 2054137 T3 ES2054137 T3 ES 2054137T3
Authority
ES
Spain
Prior art keywords
polyalcohol
conjugates
derivatised
protein
polyalcohols
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90107187T
Other languages
English (en)
Inventor
Hansjorg Dr Sinn
Hans-Hermann Schrenk
Wolfgang Dr Maier-Borst
Eckhard Dr Friedrich
Georgi Dr Graschew
Dieter Prof Dr Wohrle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Application granted granted Critical
Publication of ES2054137T3 publication Critical patent/ES2054137T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

EL INVENTO SE REFIERE A UN CONJUGADO QUE CONSISTE EN UN POLIALCOHOL O UN POLIALCOHOL DERIVADO, UN AGENTE ACTIVO, UNA PROTEINA Y UN LEVOISOMERO; SE UTILIZA PARA POSIBILITAR UN DIAGNOSTICO TUMORAL SEGUN LA MEDICINA NUCLEAR, SE EMPLEA EN PROCEDIMIENTOS DE LOCALIZACIONES DE TUMORES SEGUN DIAGNOSTICO DE RAYOS X, COMPOTERTOMOGRAFIA, SPRINTOMOGRAFIA NUCLEAR, ESPECTROCOPIA, RESNONANCIA, SPIN, ELECTRON O MICROSCOPIA ELECTRONICA Y SE CARACTERIZA PORQUE EL POLIALCOHOL O EL POLIALCOHOL DERIVADO DEL SISTEMA DE DEFENSA DE UN ORGANISMO SON POLIALCOHOL CONOCIDO NO RECONOCIDO COMO CUERPOS AMIGOS Y LA PROTEINA DEL SISTEMA DE DEFENSA DEL ORGANISMO NO ES UNA PROTEINA AMIGA RECONOCIDA DEL TUMOR ESPECIFICO O NO ESPECIFICO.
ES90107187T 1989-04-19 1990-03-14 Conjugados para la localizacion y/o la terapia de los tumores. Expired - Lifetime ES2054137T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3912792A DE3912792A1 (de) 1989-04-19 1989-04-19 Konjugate zur tumorlokalisation und/oder tumortherapie, verfahren zu ihrer herstellung sowie diese enthaltende diagnostika und/oder therapeutika

Publications (1)

Publication Number Publication Date
ES2054137T3 true ES2054137T3 (es) 1994-08-01

Family

ID=6378961

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90107187T Expired - Lifetime ES2054137T3 (es) 1989-04-19 1990-03-14 Conjugados para la localizacion y/o la terapia de los tumores.

Country Status (7)

Country Link
EP (1) EP0398024B1 (es)
JP (1) JPH0819156B2 (es)
AT (1) ATE85894T1 (es)
DE (2) DE3912792A1 (es)
DK (1) DK0398024T3 (es)
ES (1) ES2054137T3 (es)
GR (1) GR3007136T3 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4334317A1 (de) * 1993-10-08 1995-04-13 Dombaj Gmbh Vorrichtung zur Trennung von dissoziierte Stoffe enthaltenden Flüssigkeitsströmen
DE4435087A1 (de) * 1994-09-30 1996-04-04 Deutsches Krebsforsch Konjugat zur Behandlung von Infektions-, Autoimmun- und Hauterkrankungen
GB0609370D0 (en) * 2006-05-11 2006-06-21 Mock Graham A Process for cross-linking macromolecules
JP2010054305A (ja) * 2008-08-27 2010-03-11 Tohoku Denshi Sangyo Kk 癌罹病の検定に使用するデータの収集方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4466951A (en) * 1982-11-12 1984-08-21 University Of California Intracellular trapping of therapeutics or tracer agents

Also Published As

Publication number Publication date
DE59000908D1 (de) 1993-04-01
ATE85894T1 (de) 1993-03-15
DE3912792A1 (de) 1990-10-25
EP0398024A1 (de) 1990-11-22
GR3007136T3 (es) 1993-07-30
EP0398024B1 (de) 1993-02-24
JPH0334999A (ja) 1991-02-14
JPH0819156B2 (ja) 1996-02-28
DK0398024T3 (da) 1993-03-29

Similar Documents

Publication Publication Date Title
Hussain et al. Modern diagnostic imaging technique applications and risk factors in the medical field: a review
Wehrl et al. Pre-clinical PET/MR: technological advances and new perspectives in biomedical research
Schlemmer et al. Simultaneous MR/PET imaging of the human brain: feasibility study
US8041409B2 (en) Method and apparatus for multi-modal imaging
US4577636A (en) Method for diagnosis of atherosclerosis
US20150208994A1 (en) Ct/mri integrated system for the diagnosis of acute strokes and methods thereof
Beyer et al. The future of hybrid imaging—part 3: PET/MR, small-animal imaging and beyond
US10517964B2 (en) Optical imaging probes, optical imaging systems, methods of optical imaging, and methods of using optical imaging probes
Morris et al. Diagnostic imaging
Lois et al. Effect of MR contrast agents on quantitative accuracy of PET in combined whole-body PET/MR imaging
Pratt et al. Prospective testing of clinical Cerenkov luminescence imaging against standard-of-care nuclear imaging for tumour location
Basha et al. Diagnostic performance of 18 F-FDG PET/CT and whole-body MRI before and early after treatment of multiple myeloma: a prospective comparative study
Youn et al. In vivo non invasive molecular imaging for immune cell tracking in small animals
US20100292563A1 (en) Optical MRI device
Iftimia et al. Advances in Optical Imaging for Clinical Medicine
Hasegawa et al. Dual-modality imaging: more than the sum of its components
Bindseil et al. First image from a combined positron emission tomography and field‐cycled MRI system
ES2054137T3 (es) Conjugados para la localizacion y/o la terapia de los tumores.
Prasad et al. Imaging Techniques in Veterinary Disease Diagnosis
EP3469401B1 (en) Imaging technologies
Mallard The noes have it! Do they? Silvanus Thompson Memorial Lecture, February 18, 1981
Kim et al. An aptamer‐based magnetic resonance imaging contrast agent for detecting oligomeric amyloid‐β in the brain of an Alzheimer's disease mouse model
Zhou et al. Development of high-resolution molecular phase-contrast stereoscopic X-ray imaging for accurate cancer diagnostics
Ghosh et al. MRI, CT, and PETSCAN: Engineer’s Perspective
Brooks et al. Renal scans in urologic diagnosis using neohydrin Hg-203

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 398024

Country of ref document: ES